Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET
Company Participants
Walter Klemp – Chairman and Chief Executive Officer
Jonathan Foster – Executive Vice President and Chief Financial Officer
Conference Call Participants
Jonathan Aschoff – ROTH Capital
Operator
Hello, and welcome to the Moleculin Biotech Inaugural Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] Following the presentation, there will be a question-and-answer session. Note that this webcast is being recorded at the company’s request, and a replay will be made available on the company’s website following the end of the event.
At this time, I’d like to remind our listeners that remarks made during this webcast may state management’s intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risk and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements.
Some of the factors that could cause actual results to different materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with Securities and Exchange Commission. These documents are available on the investor section of the company’s website and on the Securities and Exchange Commission’s website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company’s own estimates in research. While the company believes these third-party sources to be reliable, as the date of this presentation is not independently verified and makes no representation as to the adequacy, fairness, accuracy, or completeness of any of the independent sources is verified any information obtained from third-party sources.
Joining us on today’s call from Moleculin leadership team are Walter Klemp, Chairman and Chief Executive Officer; and Jonathan Foster, Executive Vice President and Chief Financial Officer.
I’d now like to turn the conference over to Walter Klemp. Please go ahead.
Walter Klemp
Welcome, everyone. Today’s marks an important moment for the company as we kick off our inaugural earnings call. We’re proud of the fact that our clinical trials have been progressing according to plan and we’ve arrived at a point where our vision and our hope for our pipeline are now being validated by significant data. And I’m pleased to say that this progress in these data are beginning to drive a noteworthy evolution of the company. Three Phase 1/2 clinical trials are now underway for Annamycin and we just announced a follow-up report from an independent expert that continues to document the complete absence of cardiotoxicity for what we believe is a remarkable anthracycline.